These findings implied that HSPA8 inhibition caused RIP3-dependent necroptosis and offered light on the possibility of using simultaneous necroptosis inhibition to reduce the toxicity and side effects of HSPA8 inhibitor therapy in patients with autoimmune disorders or cancer. Here, HSPA8 is linked to autoimmune disease.